Mantle cell lymphoma future or investigational therapies

Jump to navigation Jump to search

Mantle cell lymphoma Microchapters


Patient Information


Historical Perspective




Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice


History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy



Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Mantle cell lymphoma future or investigational therapies

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma future or investigational therapies

on Mantle cell lymphoma future or investigational therapies

Mantle cell lymphoma future or investigational therapies in the news

Blogs on Mantle cell lymphoma future or investigational therapies

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Investigational therapies


  1. Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven E. Coutre, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert Yu, Wayne R. Godfrey & Nina D. Wagner-Johnston (2014). "A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)". Blood. 123 (22): 3398–3405. doi:10.1182/blood-2013-11-537555. PMID 24615778. Unknown parameter |month= ignored (help)
  2. Toby A. Eyre, Harriet S. Walter, Sunil Iyengar, George Follows, Matthew Cross, Christopher P. Fox, Andrew Hodson, Josh Coats, Santosh Narat, Nick Morley, Martin J. S. Dyer & Graham P. Collins (2018). "Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy". Haematologica. doi:10.3324/haematol.2018.198812. PMID 30190341. Unknown parameter |month= ignored (help)
  3. James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert P. T. Somerville, Robert O. Carpenter, Maryalice Stetler-Stevenson, James C. Yang, Giao Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, Andre Goy, Tatyana Feldman, David E. Spaner, Michael L. Wang, Clara C. Chen, Sarah M. Kranick, Avindra Nath, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey & Steven A. Rosenberg (2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33 (6): 540–549. doi:10.1200/JCO.2014.56.2025. PMID 25154820. Unknown parameter |month= ignored (help)
  4. Elahe A. Mostaghel, Paul S. Martin, Stephen Mongovin, Shani Frayo, Ailin Zhang, Kerstin L. Edlefsen, Oliver W. Press & Ajay K. Gopal (2017). "Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications". Experimental hematology. 49: 34–38. doi:10.1016/j.exphem.2017.01.001. PMID 28115200. Unknown parameter |month= ignored (help)
  5. Hun J. Lee, Maria Badillo, Jorge Romaguera & Michael Wang (2018). "A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma". British journal of haematology. doi:10.1111/bjh.15107. PMID 29527676. Unknown parameter |month= ignored (help)


Template:WH Template:WS